Whole Body PET-MRI in Paediatric and Adolescent Lymphoma
- Conditions
- Lymphoma
- Registration Number
- NCT02935348
- Lead Sponsor
- University College, London
- Brief Summary
Children and adolescents with Hodgkin lymphoma currently undergo multiple investigations including a separate PET and MRI scans during their treatment.
Investigators want to investigate if a combined PET-MRI scan could give the same information.
Children who join our study will have an extra scan twice during their treatment
- Detailed Description
Children and adolescents with Hodgkin lymphoma currently undergo multiple investigations including a separate PET and MRI scans during their treatment.
Investigators want to investigate if a combined PET-MRI scan could give the same information.
Children who join our study will have an extra scan twice during their treatment
Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 25
- Suspected or histologically confirmed Hodgkin lymphoma
- Male or female participants
- Age 0-20 years inclusive
- Entered into the EuroNet PHL-C1 trial, LP1 trial or successor Euronet trials, including Euronet PHL C2 due to open from 2013 onwards or planned to receive chemotherapy regimens of said trials without being formally entered into the trial.
- Participant/Guardian/Parental written informed consent
- Participants with contraindications to MRI (including cardiac pacemakers or non-MRI compatible intracranial vascular clips)
- Participants who are pregnant or nursing
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The investigator will determine the technical feasibility of performing functional co-registered combined PET-MRI in this patient group using diffusion-weighted MR imaging. 3 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre for Medical Imaging
🇬🇧London, United Kingdom